SRR6079996
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- PROTEIN_SECRETION+0.470
- UV_RESPONSE_DN+0.410
- INTERFERON_ALPHA_RESPONSE+0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- UNFOLDED_PROTEIN_RESPONSE+0.330
- MTORC1_SIGNALING+0.300
- GLYCOLYSIS+0.280
- MITOTIC_SPINDLE+0.270
- E2F_TARGETS+0.250
Top 10 suppressed
- KRAS_SIGNALING_DN-0.350
- ALLOGRAFT_REJECTION-0.220
- ESTROGEN_RESPONSE_EARLY-0.210
- ESTROGEN_RESPONSE_LATE-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- APICAL_SURFACE-0.170
- MYC_TARGETS_V1-0.140
- MYC_TARGETS_V2-0.120
- MYOGENESIS-0.080
- OXIDATIVE_PHOSPHORYLATION-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ED604501-C110-4693-820B-DE9FB648FEAA | — | — | 0.719 |
| 2 | TCGA-CQ-A4CG-01A-11R-A266-07 | — | — | 0.715 |
| 3 | BS_1A6MQ9ZA | high-grade glioma | — | 0.715 |
| 4 | SNU886_LIVER | HCC | — | 0.712 |
| 5 | TCGA-D8-A1XT-01A-11R-A14M-07 | — | C | 0.705 |
| 6 | TCGA-D8-A1JJ-01A-31R-A14M-07 | — | C | 0.692 |
| 7 | TCGA-78-7145-01A-11R-2039-07 | — | cohortA1 | 0.690 |
| 8 | SRR934746 | — | — | 0.685 |
| 9 | SRR10900013 | — | — | 0.684 |
| 10 | SRR12696773 | — | — | 0.678 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.470 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.250 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |